Jump to main content
Jump to site search

Issue 6, 2015
Previous Article Next Article

Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation

Author affiliations

Abstract

The phenol of 1-(3-(1H-imidazol-1-yl)propyl)-3-(4-hydroxy-3-methoxyphenyl)thiourea was selectively carbon-11 labelled to generate [11C]PBD150 in 7.3% yield from [11C]methyl triflate (non-decay corrected; radiochemical purity ≥95%, specific activity = 5.7 Ci μmol−1, n = 5). Evaluation of [11C]PBD150 by small animal PET imaging (mouse and rat) determined it does not permeate the blood brain barrier, indicating previously described therapeutic effect in transgenic mice was likely not the result of inhibiting central nervous system glutaminyl cyclase.

Graphical abstract: Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Apr 2015, accepted on 21 Apr 2015 and first published on 22 Apr 2015


Article type: Concise Article
DOI: 10.1039/C5MD00148J
Author version
available:
Download author version (PDF)
Citation: Med. Chem. Commun., 2015,6, 1065-1068
  •   Request permissions

    Synthesis and evaluation of [11C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation

    A. F. Brooks, I. M. Jackson, X. Shao, G. W. Kropog, P. Sherman, C. A. Quesada and P. J. H. Scott, Med. Chem. Commun., 2015, 6, 1065
    DOI: 10.1039/C5MD00148J

Search articles by author

Spotlight

Advertisements